Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $407.57 million. The enterprise value is $204.89 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 88.60 million shares outstanding. The number of shares has increased by 7.53% in one year.
| Current Share Class | 88.60M |
| Shares Outstanding | 88.60M |
| Shares Change (YoY) | +7.53% |
| Shares Change (QoQ) | +24.93% |
| Owned by Insiders (%) | 9.23% |
| Owned by Institutions (%) | 50.38% |
| Float | 58.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -320.42 |
| Forward PS | n/a |
| PB Ratio | 2.04 |
| P/TBV Ratio | 2.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.05, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.05 |
| Quick Ratio | 11.40 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -83.24% and return on invested capital (ROIC) is -48.87%.
| Return on Equity (ROE) | -83.24% |
| Return on Assets (ROA) | -40.72% |
| Return on Invested Capital (ROIC) | -48.87% |
| Return on Capital Employed (ROCE) | -102.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.78M |
| Employee Count | 123 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -635,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +162.11% in the last 52 weeks. The beta is -0.59, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.59 |
| 52-Week Price Change | +162.11% |
| 50-Day Moving Average | 4.04 |
| 200-Day Moving Average | 3.75 |
| Relative Strength Index (RSI) | 51.92 |
| Average Volume (20 Days) | 1,051,343 |
Short Selling Information
The latest short interest is 4.20 million, so 4.74% of the outstanding shares have been sold short.
| Short Interest | 4.20M |
| Short Previous Month | 4.31M |
| Short % of Shares Out | 4.74% |
| Short % of Float | 7.20% |
| Short Ratio (days to cover) | 5.68 |
Income Statement
In the last 12 months, AMLX had revenue of -$1.27 million and -$218.86 million in losses. Loss per share was -$3.02.
| Revenue | -1.27M |
| Gross Profit | -113.58M |
| Operating Income | -207.55M |
| Pretax Income | -162.36M |
| Net Income | -218.86M |
| EBITDA | -206.81M |
| EBIT | -207.55M |
| Loss Per Share | -$3.02 |
Full Income StatementBalance Sheet
The company has $204.07 million in cash and $1.38 million in debt, giving a net cash position of $202.69 million or $2.29 per share.
| Cash & Cash Equivalents | 204.07M |
| Total Debt | 1.38M |
| Net Cash | 202.69M |
| Net Cash Per Share | $2.29 |
| Equity (Book Value) | 201.42M |
| Book Value Per Share | 2.26 |
| Working Capital | 198.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$206.98 million and capital expenditures -$36.30 million, giving a free cash flow of -$243.29 million.
| Operating Cash Flow | -206.98M |
| Capital Expenditures | -36.30M |
| Free Cash Flow | -243.29M |
| FCF Per Share | -$2.75 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | 16,317.06% |
| Pretax Margin | 17,255.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |